Drug Interaction Report

Buprenorphine and Levoketoconazole: Interaction Details

AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature

Buprenorphine

Belbuca Brixadi Buprenex BuTrans Simbadol Sublocade Zorbium
+

Levoketoconazole

Recorlev Recorlev®
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by
Updated Jul 2, 2026
LinkedIn
Interaction severity
Contraindicated
These should generally not be used together.
How we grade severity & evidence

Severity levels

  • Contraindicated: These should generally not be used together.
  • Major: Potentially serious — often needs a change or close monitoring.
  • Moderate: Can be significant — usually manageable with monitoring.
  • Minor: Usually limited clinical impact.

Evidence grades

  • Established: Well documented — supported by controlled studies or strong clinical data.
  • Probable: Good supporting evidence, though not definitively proven.
  • Suspected: Some evidence suggests this interaction, but it is not well established.
  • Possible: Limited or conflicting evidence; the interaction may occur.
  • Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Of 633 documented Buprenorphine interactions, 22 are rated contraindicated — including this one.
Worried about symptoms right now? Contact your pharmacist or prescriber, or call Poison Control at 1-800-222-1222 (US). Call 911 for an emergency.
At a glance + Theoretical Effects may be stronger
The Bottom Line
Buprenorphine and levoketoconazole are contraindicated together because they can both prolong the QT interval and levoketoconazole can raise buprenorphine levels; talk to your prescriber or pharmacist before combining them.

These two medicines can be a risky pair. Buprenorphine (a pain or opioid-dependence medicine) and levoketoconazole (Recorlev, used for Cushing's syndrome) can each affect your heart's rhythm. Together they can add up and cause a heart rhythm change called QT prolongation, which in rare cases can be dangerous.

On top of that, levoketoconazole slows down the liver enzyme (CYP3A4) that clears buprenorphine, so buprenorphine can build up and cause stronger effects like drowsiness or slowed breathing. Because of this, the two are usually not used together. The good news: your care team can spot this and manage it, often by choosing a different medicine and by monitoring your heart with an ECG. Please talk with your pharmacist or doctor before combining them.

Contraindicated combination. Two concerns:

  • Additive QT prolongation: both agents can prolong the QT interval, raising torsades de pointes risk. Levoketoconazole labeling contraindicates use with known QT-prolonging drugs.
  • PK interaction: levoketoconazole is a potent CYP3A4 inhibitor; buprenorphine is a CYP3A4 substrate. Inhibition reduces buprenorphine clearance, increasing exposure (AUC/Cmax) and opioid-related adverse effects (sedation, respiratory depression).

Evidence is theoretical; onset unspecified. Management: avoid coadministration. If unavoidable, frequent ECG monitoring, electrolyte correction, and close observation for opioid toxicity with individualized dose adjustment by the care team.

Onset
unspecified
Evidence
theoretical
Severity
Contraindicated

What happens

An increased risk of QT interval prolongation and torsades pointes, an increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse reactions

Interaction Deep Dive

Patients receiving medications recognized to prolong the QT interval should not be given levoketoconazole, as this combination is contraindicated. ECG monitoring should be performed frequently. When levoketoconazole is administered together with CYP3A4 substrates, exposure to those CYP3A4 substrates may rise, potentially leading to more adverse reactions associated with the CYP3A4 substrate1.

Why it happens (mechanism)

Additive QT interval prolongation; inhibition of CYP3A4-substrate metabolism by levoketoconazole

How to manage this interaction

Because this pair is flagged as contraindicated, the usual approach is to avoid using them together.

  • Your care team may choose a different medicine for either the pain/opioid-dependence need or the Cushing's treatment.
  • If both are truly needed, expect frequent ECG checks to watch your heart rhythm and closer monitoring for opioid side effects like drowsiness or slowed breathing. Your buprenorphine dose may need to be adjusted and individualized by your care team.

What to do: Keep taking both exactly as prescribed and do not stop on your own. Contact your pharmacist or prescriber promptly so they can review this combination.

Management is individual — confirm any change with your pharmacist or prescriber.

Common questions

Can I take Buprenorphine and Levoketoconazole together?

Buprenorphine and levoketoconazole are contraindicated together because they can both prolong the QT interval and levoketoconazole can raise buprenorphine levels; talk to your prescriber or pharmacist before combining them. Always confirm with your pharmacist or prescriber before making any change.

How serious is the Buprenorphine and Levoketoconazole interaction?

It is rated contraindicated. These should generally not be used together.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How is the Buprenorphine and Levoketoconazole interaction managed?

Because this pair is flagged as contraindicated, the usual approach is to avoid using them together. Your care team may choose a different medicine for either the pain/opioid-dependence need or the Cushing's treatment. If both are truly needed, expect frequent ECG checks to watch your heart rhythm and closer monitoring for opioid side effects like drowsiness or slowed breathing. Your buprenorphine… Management is individual — always follow your own care team's guidance.

How strong is the evidence for this interaction?

The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.

Questions for your pharmacist

  • Does my dose of Buprenorphine or Levoketoconazole need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there a safer alternative to one of these medications for me?

References (1)

  1. Product Information: RECORLEV(R) oral tablets, levoketoconazole oral tablets. Xeris Pharmaceuticals Inc (per FDA), Chicago, IL, 2023. DailyMed
Was this write-up helpful?
Beyond drug–drug

These medications also interact with supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

major · moderate · minor — check everything you take with our drug–supplement interaction checker.

Check another combination

Our instant two-drug interaction checker is almost here.

Coming soon

The instant two-drug checker is on its way.

In the meantime, browse the directory below to look up any drug and see its documented interactions.

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.